Advances in Nontuberculous Mycobacterial Lung Disease: Improvement in Diagnosis, Treatment and Patient Quality of Life

Program Dates: February 8th, 2021 - February 7th, 2022
Credits: 0.75 AMA PRA Category 1 Credits™

Advances in Nontuberculous Mycobacterial Lung Disease: Improvement in Diagnosis, Treatment and Patient Quality of Life

Program Overview

This CME program is derived from content presented at the 2020-2021 Eastern Pulmonary Conference Program. The expert faculty, Drs. Sidney S. Braman and Charles L. Daley, will first highlight the prevalence and risk factors of nontuberculous mycobacterial lung disease (NTM-LD), as well as the importance of early diagnosis. Following, current criteria and treatment recommendations will be reviewed in the context of clinical decision making. The faculty will conclude with best practices for creating personalized treatment plans to improve patient outcomes and quality of life in nontuberculous mycobacterial lung disease. Upon completion of this activity, learners will be better equipped with current data to treat and manage patients with NTM-LD.

Target Audience

Pulmonologists, primary care physicians, PAs, NPs, nurses, pharmacists, and other healthcare professionals involved in the management of patients with NTM-LD

Learning Objectives

  1. Understand the epidemiology and clinical manifestations of NTM-LD, as well as risk factors for the disease
  2. Understand guideline-based diagnostic criteria and importance of the laboratory in the diagnosis of NTM-LD
  3. Describe current treatment regimens for MAC-LD
  4. Describe treatment goals, importance of adherence to treatment and quality of life


  1. Epidemiology, Clinical Manifestations, and Risk Factors for NTM Lung Disease
  2. Diagnosis of NTM Lung Disease – Review of Diagnostic Criteria
  3. Review of Current Treatment Recommendations
  4. Personalized Treatment Plans and Improving Quality of Life


Sidney S. Braman, MD
Professor of Medicine
Pulmonary, Critical Care and Sleep Medicine
Icahn School of Medicine at Mount Sinai
New York, New York



Charles L. Daley, MD
Chief, Division of Mycobacterial & Respiratory Infections
Professor, Department of Medicine
National Jewish Health
Denver, Colorado


Disclosures of Conflict of Interest

It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

Faculty Relationship Identified With:
Sidney S. Braman, MD


Consultant/Advisor: Sunovion Pharmaceuticals Inc.

Speakers Bureau: AstraZeneca Pharmaceuticals; Boehringer Ingelheim; GmbH, Inc; Genentech, Inc.

Charles L. Daley, MD


Consultant/Advisor: AN2; Cipla; Insmed; Matinas; Paratek; Spero

Grant/Research Support: Insmed; Spero Therapeutics

Planners and Peer Reviewers

Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC; Nicole McMenamin and Chelsey Benedek hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.

Accreditation Statement

In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. This activity was planned by and for the healthcare team.

Credit Designation Statements

AcademicCME designates this live material for a maximum of 0.75 AMA PRA Category 1 CreditsTM.

Participants should claim only the credit commensurate with the extent of their participation in the activity.

Financial Support

This activity has been supported by an independent educational grant from Insmed Incorporated.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Insmed Incorporated do not recommend the use of any agent outside of the labeled indications.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation

In order to claim credit, participants must complete the following:

  1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
  2. Complete the Pre-Activity Questions
  3. Read or Review the activity content.
  4. Complete the Post-Activity Test Questions and Evaluation.
  5. Learners who receive a grade of 70% or better on the Post-Activity Test Questions and complete the Evaluation will receive appropriate credit as indicated (CME, CNE, and/or CPE credit).
  • CPE credit will be posted to the learner’s CPE Monitor profile within 60 days of completion.
  • CME and CNE credit will be issued appropriate certificate of completion.
  • Others may request a “certificate of completion”.
  1. Learners should claim only the credit commensurate with the extent of their participation in the activity.

CE Inquiries/Special Needs

For all CE inquiries or special needs, please contact [email protected].



Provided by: AcademicCME-web